# Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine

> **NCT02501421** · PHASE1 · COMPLETED · sponsor: **Research Institute for Biological Safety Problems** · enrollment: 44 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** tuberculosis vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02501421
- **Lead sponsor:** Research Institute for Biological Safety Problems
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-04
- **Final completion:** 2015-02
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501421, "Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02501421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*